ASHBY breast brachytherapy trial is recruiting in PHASE2
ASHBY is a PHASE2, RECRUITING study of Accelerated Super-Hypofractionated Breast Brachytherapy, with toxicity as the main focus and an estimated primary completion date of 2031-01-31.
A new ClinicalTrials.gov registry observation shows ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy in PHASE2 and RECRUITING status. The study is sponsored by Virginia Commonwealth University, and its primary completion date is listed as 2031-01-31, so this is an ongoing trial rather than a finished one.
For a general reader, the main point is simple: the study is testing a 1.5-day APBI treatment course. APBI means Accelerated Partial Breast Irradiation, a focused form of breast radiation aimed at the treated area rather than the whole breast.
"Assess the toxicity (at 1 and 3 years) of a 1.5-day APBI treatment course" — source: ctgov_v2
What the trial is measuring
The primary outcome centers on toxicity, with APBI-related adverse events of interest occurring at grade ≥3 within 1 year and 3 years after APBI. The description also says these toxicities will be evaluated at follow-up appointments and captured from the start of study treatment until the patient is off study.
That makes the registry entry especially important for people following breast cancer care, because the study is not just asking whether the treatment can be delivered. It is also asking how the shortened course performs over time in terms of side effects and safety tracking.
"The APBI-related toxicities specified in Section 10.1 will be explicitly evaluated at all follow-up appointments." — source: ctgov_v2
How this fits the broader cancer trial stream
ASHBY appears inside the active Cancer Breakthroughs special event, alongside other cancer-focused registry observations. The linked material includes studies in breast cancer, lung cancer, colorectal cancer, cervical disease, and blood cancers, which shows a broad mix of prevention, treatment, and monitoring questions.
Within that set, ASHBY stands out for its narrow focus on breast brachytherapy and its short treatment window. The record does not provide results, so the practical takeaway is limited to status: recruitment is open, the study is active, and the main readout will come later.
"This record describes a study and its registry status; study outcomes require posted results." — source: ctgov_v2
Why readers may want to watch it
People looking for updates on shorter breast radiation schedules will want to note the design of this study, especially the 1.5-day APBI course and the long follow-up window. The registry entry suggests the central question is whether a compressed treatment course can be monitored carefully enough to understand toxicity over time.
For now, the clearest fact is that the trial is still open and its outcome is not yet posted. That means ASHBY is a live research effort, not a concluded finding, and its next significance will come from future registry updates or results posting.